{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591428,"version":"4.5.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The document comprehensively reviews proton pump inhibitors (PPIs), focusing on their pharmacodynamics, pharmacokinetics, drug interactions, toxicity, and clinical efficacy. PPIs irreversibly inhibit the H+\/K+-ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. These drugs are widely prescribed for conditions like gastroesophageal reflux disease (GERD), peptic ulcer disease, eradication of <jats:italic>Helicobacter pylori<\/jats:italic> and as a prevention against bleeding from gastrointestinal tract. The review article highlights significant drug interactions associated with PPIs. Omeprazole, for instance, can interfere with the metabolism of clopidogrel, reducing its antiplatelet efficacy, which may have clinical implications. The article also discusses other drug interactions, including anticoagulants (e.g., warfarin), selective serotonin reuptake inhibitors (SSRIs), and immunosuppressive and chemotherapeutic drugs, as well as the side effects associated with taking PPIs. Long-term use of PPIs is linked to plenty of adverse effects, such as vitamin B12 and calcium deficiencies, which can lead to bone fractures. An increased risk of infections, including <jats:italic>Clostridium difficile<\/jats:italic> and small intestinal bacterial overgrowth (SIBO), is also noted. Cardiovascular risks, such as myocardial infarction and stroke, are observed in some patients on high-dose or prolonged PPI therapy. In rare cases, nephrotoxicity and hepatotoxicity are reported. Additionally, the document examines the potential role of PPIs in exacerbating certain cancers, such as gastric adenocarcinoma, and in influencing the severity of COVID-19 symptoms. PPIs are proven effective in treating GERD and preventing complications from nonsteroidal anti-inflammatory drugs (NSAIDs), particularly in reducing the risk of NSAID-induced ulcers. The document stresses the importance of understanding drug interactions and the need for individualized treatment to minimize adverse effects. Ongoing research into PPIs\u2019 long-term safety and efficacy remains essential, particularly given their widespread use in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2025.1507812","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:14:01Z","timestamp":1753244041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"\u0141ukasz","family":"Wo\u0142owiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Osiak-Gwiazdowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ja\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Janiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Wydeheft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"\u0141ukasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pellowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Grze\u015bk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","article-title":"Proton pump inhibitors and risk of gastric cancer: population-based cohort study","volume":"71","author":"Abrahami","year":"2022","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4330\/wjc.v15.i8.375","article-title":"Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: a cardiologic point of view","volume":"15","author":"Abrignani","year":"2023","journal-title":"World J. Cardiol."},{"key":"B3","article-title":"Proton pump inhibitors (PPI)","author":"Ahmed","year":"2023","journal-title":"StatPearls"},{"key":"B4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/09537104.2019.1609667","article-title":"Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: the randomized, prospective, PROTECT trial","volume":"31","author":"Ahn","year":"2020","journal-title":"Platelets"},{"key":"B5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/bcp.15583","article-title":"Do proton pump inhibitors increase the risk of dementia? a systematic review, meta\u2010analysis and bias analysis","volume":"89","author":"Ahn","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.sdentj.2024.07.017","article-title":"Impact of proton pump inhibitors on periodontal health \u2013 a systematic review","volume":"36","author":"Aldulaijan","year":"2024","journal-title":"Saudi Dent. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2165\/00003088-200140070-00004","article-title":"Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole","volume":"40","author":"Andersson","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"B8","first-page":"177","volume-title":"Yearbook International Tribunal for the Law of the Sea\/Annuaire Tribunal international du droit de la mer","author":"Annex","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4292\/wjgpt.v5.i3.105","article-title":"Diagnosis and treatment of gastroesophageal reflux disease","volume":"5","author":"Badillo","year":"2014","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5009\/gnl19009","article-title":"The role of acid suppressants in the prevention of anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis","volume":"14","author":"Bang","year":"2020","journal-title":"Gut Liver"},{"key":"B11","first-page":"332","article-title":"Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?","volume":"19","author":"Barkas","year":"2015","journal-title":"Hippokratia"},{"key":"B12","first-page":"1","volume-title":"Pantoprazole. xPharm: the comprehensive pharmacology reference","author":"Bernshteyn","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/bcp.14267","article-title":"A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations","volume":"86","author":"Blanco","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4292\/wjgpt.v6.i2.17","article-title":"Clinical relevance of clopidogrel-proton pump inhibitors interaction","volume":"6","author":"Bouziana","year":"2015","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fmed.2018.00320","article-title":"Pantoprazole does not affect serum trough levels of tacrolimus and everolimus in liver transplant recipients","volume":"5","author":"Bremer","year":"2018","journal-title":"Front. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"798272","DOI":"10.3389\/fphar.2022.798272","article-title":"Proton pump inhibitors and cancer: current state of play","volume":"13","author":"Bridoux","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e001719","DOI":"10.1136\/bmjgast-2024-001719","article-title":"Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective","volume":"12","author":"Brusselaers","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0239464","DOI":"10.1371\/journal.pone.0239464","article-title":"Binding of omeprazole to protein targets identified by monoclonal antibodies","volume":"15","author":"Cartee","year":"2020","journal-title":"PLoS One"},{"key":"B20","volume-title":"Lehigh valley health network LVHN scholarly works features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022"},{"key":"B21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/ejhpharm-2018-001697","article-title":"Prescription of proton pump inhibitors in older adults with complex polytherapy","volume":"27","author":"Cena","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/17425255.2023.2190883","article-title":"A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens","volume":"19","author":"Chevalier","year":"2023","journal-title":"Expert Opin. Drug Metabolism and Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5009\/gnl16352","article-title":"Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea","volume":"11","author":"Choi","year":"2017","journal-title":"Gut Liver"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/life13081627","article-title":"Importance of pharmacogenetics and drug-drug interactions in a kidney transplanted patient","volume":"13","author":"Concha","year":"2023","journal-title":"Life (Basel, Switz.)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40119-023-00338-1","article-title":"Cardiovascular compatibility of proton pump inhibitors: practice recommendations","volume":"12","author":"Dalal","year":"2023","journal-title":"Cardiol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.10.005","article-title":"Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib","volume":"66","author":"Del Re","year":"2022","journal-title":"Breast Official J. Eur. Soc. Mastology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.esmoop.2021.100231","article-title":"Drug-drug interactions between palbociclib and proton pump inhibitors May significantly affect clinical outcome of metastatic breast cancer patients","volume":"6","author":"Del Re","year":"2021","journal-title":"ESMO Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1389200224666230815122312","article-title":"Molecular insights into the mechanism of modulatory effects of proton pump inhibitors on P-glycoprotein mediated drug transport of palbociclib and ribociclib","volume":"24","author":"Desai","year":"2023","journal-title":"Curr. Drug Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jamda.2020.09.046","article-title":"The use and misuse of proton pump inhibitors: an opportunity for deprescribing","volume":"22","author":"Dharmarajan","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13256-022-03337-3","article-title":"Omeprazole-induced galactorrhea in kidney transplant patients\u2014a case report","volume":"16","author":"Dorji","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/PGPM.S217725","article-title":"Antihypertensive effect of amlodipine in Co-Administration with omeprazole in patients with hypertension and acid-related disorders: cytochrome P450-Associated aspects","volume":"12","author":"Dorofeeva","year":"2019","journal-title":"Pharmacogenomics Personalized Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/jpm11050367","article-title":"Interaction between omeprazole and gliclazide in relation to CYP2C19 phenotype","volume":"11","author":"Dujic","year":"2021","journal-title":"J. Personalized Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El","year":"2018","journal-title":"Expert Opin. drug metabolism and Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1152\/physrev.00016.2019","article-title":"The physiology of the gastric parietal cell","volume":"100","author":"Engevik","year":"2020","journal-title":"Physiol. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s40800-015-0012-6","article-title":"Diclofenac- and pantoprazole-induced rhabdomyolysis: a potential drug interaction","volume":"2","author":"Ertekin","year":"2015","journal-title":"Drug Saf. - Case Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00228-018-2564-8","article-title":"Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000\u20132016","volume":"75","author":"Farhat","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/tropicalmed7030037","article-title":"The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis","volume":"7","author":"Fatima","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"B38","volume-title":"Drug interactions: what you should know.","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/cts.12465","article-title":"No pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir\/grazoprevir and famotidine or pantoprazole","volume":"10","author":"Feng","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/apm.12380","article-title":"Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival","volume":"123","author":"Fossmark","year":"2015","journal-title":"APMIS"},{"key":"B41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ueg2.12146","article-title":"Effectiveness of PPI treatment and guideline adherence in 236 patients with eosinophilic oesophagitis\u2014Results from the population-based DanEoE cohort shows a low complication rate","volume":"9","author":"Frandsen","year":"2021","journal-title":"United Eur. Gastroenterology J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e32228","DOI":"10.1097\/MD.0000000000032228","article-title":"Use of proton pump inhibitors for the risk of gastric cancer","volume":"101","author":"Gao","year":"","journal-title":"Medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2022.794931","article-title":"The influence of CYP3A4 genetic polymorphism and proton pump inhibitors on osimertinib metabolism","volume":"13","author":"Gao","year":"","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.amjms.2021.05.017","article-title":"The effect of proton pump inhibitor use on the course of kidney function in patients with chronic kidney disease stages G3a to G4","volume":"362","author":"Giusti","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","article-title":"Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline","volume":"37","author":"Gjestad","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"B46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13318-018-0480-z","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, safety, and tolerability of roxadustat in healthy subjects","volume":"43","author":"Groenendaal-van de Meent","year":"2018","journal-title":"Eur. J. Drug Metabolism Pharmacokinet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"620","DOI":"10.21873\/cdp.10151","article-title":"Examination of the effect of proton pump inhibitors on the anticancer activity of oxaliplatin","volume":"2","author":"Hashizume","year":"2022","journal-title":"Cancer diagnosis and prognosis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1345\/aph.1M519","article-title":"Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease","volume":"44","author":"Higginbotham","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.cgh.2021.05.011","article-title":"Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis","volume":"19","author":"Israelsen","year":"2021","journal-title":"Clin. Gastroenterology Hepatology Official Clin. Pract. J. Am. Gastroenterological Assoc."},{"key":"B51","first-page":"1","volume-title":"Lansoprazole. xPharm: the comprehensive pharmacology reference","author":"Jewell","year":"2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/cpt.1949","article-title":"Effect of high-dose esomeprazole on CYP1A2, CYP2C19, and CYP3A4 activities in humans: evidence for substantial and long-lasting inhibition of CYP2C19","volume":"108","author":"Kaartinen","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jphs.2019.03.001","article-title":"Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype","volume":"139","author":"Kamiya","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00464-018-6409-4","article-title":"Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis","volume":"33","author":"Kim","year":"2019","journal-title":"Surg. Endosc."},{"key":"B56","first-page":"1","volume-title":"Hypomagnesemia, cardiovascular disease and other adverse effects in long term users of proton pump inhibitors","author":"Kitchlew","year":"2023"},{"key":"B57","doi-asserted-by":"publisher","first-page":"116668","DOI":"10.1016\/j.bone.2022.116668","article-title":"Bone microstructure in proton pump inhibitor users","volume":"168","author":"Kondapalli","year":"2023","journal-title":"Bone"},{"key":"B58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.therap.2020.06.019","article-title":"Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations","volume":"76","author":"Koyyada","year":"2021","journal-title":"Therapies"},{"key":"B59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/pharmaceutics15010023","article-title":"Roles of human liver cytochrome P450 enzymes in tenatoprazole metabolism","volume":"15","author":"Le","year":"2023","journal-title":"Pharmaceutics"},{"key":"B119","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/gutjnl-2020-322248","article-title":"Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching","volume":"70","author":"Lee","year":"2021","journal-title":"Gut"},{"key":"B60","first-page":"19","article-title":"Review of the long-term effects of proton pump inhibitors","volume":"34","author":"Lehault","year":"2017","journal-title":"Fed. Pract."},{"key":"B61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3310\/hta11510","article-title":"Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding","volume":"11","author":"Leontiadis","year":"2007","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"B62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/13543776.2013.741121","article-title":"H+\/K+-ATPase inhibitors: a patent review","volume":"23","author":"Li","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"B63","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-019-03915-1","article-title":"A drug\u2013drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics","volume":"84","author":"Li","year":"","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e14422","DOI":"10.1097\/MD.0000000000014422","article-title":"Proton pump inhibitor use and risk of dementia: systematic review and meta-analysis","volume":"98","author":"Li","year":"","journal-title":"Medicine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cpdd.1110","article-title":"Effects of CYP3A inhibition, CYP3A induction, and gastric acid reduction on the pharmacokinetics of ripretinib, a switch control KIT tyrosine kinase inhibitor","volume":"11","author":"Li","year":"","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1111\/bcp.15169","article-title":"Clinical study of drug\u2013drug interaction between omeprazole and pyrotinib after meal","volume":"88","author":"Li","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/sjg.SJG_573_16","article-title":"Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: a meta-analysis","volume":"23","author":"Li","year":"2017","journal-title":"Saudi J. Gastroenterology"},{"key":"B68","first-page":"361","article-title":"Complicated gastroesophageal reflux disease \u2013 therapeutic dilemmas","volume":"19","author":"Liakakos","year":"2010","journal-title":"Adv. Clin. Exp. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1111\/cts.13620","article-title":"CYP2C19 genotypes and osteoporotic fractures in long-term users of proton pump inhibitors: a hospital-based study","volume":"16","author":"Liao","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"E23695","DOI":"10.1097\/MD.0000000000023695","article-title":"Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay","volume":"99","author":"Lin","year":"2020","journal-title":"Med. (United States)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.2147\/PGPM.S329662","article-title":"Analysis of combined effect of CYP2C19 genetic polymorphism and proton pump inhibitors coadministration on trough concentration of voriconazole","volume":"14","author":"Mafuru","year":"2021","journal-title":"Pharmacogenomics Personalized Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.3390\/ijms20236031","article-title":"The phylogeny and biological function of gastric juice\u2014microbiological consequences of removing gastric acid","volume":"20","author":"Martinsen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"115149","DOI":"10.1016\/j.biopha.2023.115149","article-title":"Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients \u2013 a review","volume":"166","author":"Miedziaszczyk","year":"2023","journal-title":"Biomed. and Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcph.1496","article-title":"Effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: a study with the modified cooperstown 5+1 cocktail","volume":"60","author":"Mohamed","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00280-023-04554-3","article-title":"Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors","volume":"92","author":"N\u00e5g\u00e5rd","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ahj.2015.05.017","article-title":"Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes trial","volume":"170","author":"Nicolau","year":"2015","journal-title":"Am. Heart J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e22163","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"B80","doi-asserted-by":"publisher","first-page":"425353","DOI":"10.3389\/fneur.2018.01142","article-title":"PPI long term use: risk of neurological adverse events?","volume":"10","author":"Novotny","year":"2019","journal-title":"Front. Neurology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40360-020-00433-2","article-title":"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole","volume":"21","author":"Ochoa","year":"2020","journal-title":"BMC Pharmacol. and Toxicol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/medicina59030557","article-title":"Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer?","volume":"59","author":"Odabas","year":"2023","journal-title":"Medicina"},{"key":"B83","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1389200221666200218121050","article-title":"Clinical impact of Co-medication of levetiracetam and clobazam with proton pump inhibitors: a drug interaction study","volume":"21","author":"Pasupuleti","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3457890","DOI":"10.1155\/2020\/3457890","article-title":"Pharmacological effects and toxicogenetic impacts of omeprazole: genomic instability and cancer","volume":"2020","author":"Paz","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B85","volume-title":"Proton pump inhibitors","year":"2012"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.01.011","article-title":"Evaluating the effect of six proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"27","author":"Przespolewski","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis. Official J. Natl. Stroke Assoc."},{"key":"B87","doi-asserted-by":"publisher","first-page":"570835","DOI":"10.3389\/fphar.2021.570835","article-title":"Hypoglycemia associated with drug\u2013drug interactions in patients with type 2 diabetes mellitus using Dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Ray","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.2165\/00003495-200363240-00004","article-title":"Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know","volume":"63","author":"Robinson","year":"2003","journal-title":"Drugs"},{"key":"B89","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/apt.16239","article-title":"Impact of proton pump inhibitors on cytochrome P450 activity assessed by 13 C-aminopyrine breath test in patients with cirrhosis","volume":"53","author":"Rocco","year":"2021","journal-title":"Alimentary Pharmacol. and Ther."},{"key":"B90","first-page":"207","volume-title":"Prehension and hafting traces on flint tools","author":"Rots","year":"2019"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Alimentary Pharmacol. and Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.2014.856883","article-title":"Antiplatelet drug interactions with proton pump inhibitors","volume":"10","author":"Scott","year":"2014","journal-title":"Expert Opin. drug metabolism and Toxicol."},{"key":"B94","first-page":"151","article-title":"Omeprazole","volume":"35","author":"Shah","year":"2023","journal-title":"Profiles Drug Subst. Excipients Relat. Methodol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00280-018-3748-8","article-title":"Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study","volume":"83","author":"Shaik","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pharma.2022.08.013","article-title":"What is the role of proton pump inhibitors consumption on the clinical presentation and severity of COVID-19 infection?","volume":"81","author":"Shokri","year":"2023","journal-title":"Ann. Pharm. Francaises"},{"key":"B98","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1345\/aph.1C396","article-title":"Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction","volume":"37","author":"Sipe","year":"2003","journal-title":"Esomeprazole, Clarithromycin Interact."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00228-018-2514-5","article-title":"Clinically relevant drug\u2013drug interactions among elderly people with dementia","volume":"74","author":"S\u00f6nnerstam","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/pharmaceutics14102043","article-title":"Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives","volume":"14","author":"Srebro","year":"2022","journal-title":"Pharmaceutics"},{"key":"B101","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/87551225231166531","article-title":"Vonoprazan: a new potassium-competitive acid blocker","volume":"39","author":"St. Onge","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut liver"},{"key":"B103","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2141.2011.08633.x","article-title":"Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment","volume":"153","author":"Teichert","year":"2011","journal-title":"Br. J. Haematol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/CPAA.S106234","article-title":"A case of probable esomeprazole-induced transient liver injury in a pregnant woman with hyperemesis","volume":"8","author":"Thomas","year":"2016","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e0020721","DOI":"10.1128\/AAC.00207-21","article-title":"Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients","volume":"65","author":"Tian","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3748\/wjg.v28.i24.2667","article-title":"Rebuilding trust in proton pump inhibitor therapy","volume":"28","author":"Turshudzhyan","year":"2022","journal-title":"World J. Gastroenterology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/ajh.26581","article-title":"Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial","volume":"97","author":"van Vuren","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/bcp.15103","article-title":"Association of proton-pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials","volume":"88","author":"Veettil","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"462","DOI":"10.23736\/S2724-6051.21.04116-3","article-title":"Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease","volume":"73","author":"Vengrus","year":"2021","journal-title":"Minerva Urology Nephrol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/TCRM.S80437","article-title":"Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy","volume":"11","author":"Wang","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"B111","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf."},{"key":"B112","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/metabo11020096","article-title":"Use of clopidogrel and proton pump inhibitors alone or in combinations in persons with diabetes in Denmark; potential for CYP2C19 genotype-guided drug therapy","volume":"11","author":"Westergaard","year":"2021","journal-title":"Metabolites"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e30532","DOI":"10.1097\/MD.0000000000030532","article-title":"Effect of proton pump inhibitors on the clinical outcomes of PD-1\/PD-L1 inhibitor in solid cancer patients","volume":"101","author":"Wu","year":"2022","journal-title":"Medicine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e011607","DOI":"10.1161\/JAHA.118.011607","article-title":"Cardiovascular outcomes associated with clinical use of citalopram and omeprazole: a nationwide population-based cohort study","volume":"8","author":"Wu","year":"2019","journal-title":"J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis."},{"key":"B115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7883\/yoken.JJID.2021.074","article-title":"Does proton pump inhibitor use lead to a higher risk of coronavirus disease 2019 infection and progression to severe disease? a meta-analysis","volume":"75","author":"Yan","year":"2022","journal-title":"Jpn. J. Infect. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1053\/j.gastro.2019.02.036","article-title":"Gastric parietal cell physiology and helicobacter pylori\u2013Induced disease","volume":"156","author":"Yao","year":"2019","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e13917","DOI":"10.7759\/cureus.13917","article-title":"A case of dysembryoplastic neuroepithelial tumor in an adolescent Male","volume":"13","author":"Yibirin","year":"2021","journal-title":"Cureus"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1136\/gutjnl-2020-323668","article-title":"Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study","volume":"70","author":"Zhou","year":"2021","journal-title":"Gut"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1507812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:14:04Z","timestamp":1753244044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1507812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":119,"alternative-id":["10.3389\/fphar.2025.1507812"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1507812","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"article-number":"1507812"}}